Literature DB >> 33910869

Clinical Characteristics and Outcome of Pathologic N0 Non-small Cell Lung Cancer Patients With False Positive Mediastinal Lymph Node Metastasis on FDG PET-CT.

Kyu Yean Kim1, Hye Lim Park2, Hye Seon Kang1, Hwa Young Lee1, Ie Ryung Yoo3, Sang Haak Lee1, Chang Dong Yeo4.   

Abstract

BACKGROUND/AIM: Preoperative fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) is a non-invasive and useful diagnostic tool to evaluate mediastinal lymph node (LN) metastasis in lung cancer. However, there are often false-positive LN cases in FDG PET-CT. This study aimed to explore the clinical characteristics and outcome of pathologic N0 non-small cell lung cancer patients with false-positive mediastinal LN on FDG PET-CT. PATIENTS AND METHODS: We enrolled 147 patients who underwent preoperative FDG PET-CT scan and mediastinal LN dissection. These patients were re-evaluated for post-operative pathologic nodal metastasis and divided into a false-positive group and a group of others.
RESULTS: Among 40 patients diagnosed with clinical N1-3 on FDG PET-CT, 19 (47.5%) patients were pathologic N0, meaning false-positive LN by PET-CT. Preoperative absolute platelet count and platelet-lymphocyte ratio were significantly higher in patients with pathologic N0. The presence of lymphatic invasion was significantly lower in patients with pathologic N0 than in the group of others. Recurrence-free survival was significantly shorter in patients with false positive LN than in patients with true positive LN or true negative LN at the same pathologic stage.
CONCLUSION: Higher absolute platelet count and PLR, lower proportion of lymphatic invasion and shorter recurrence-free survival were associated with false positive mediastinal LN on preoperative FDG PET-CT. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  FDG PET-CT; Lung cancer; false-positive

Mesh:

Substances:

Year:  2021        PMID: 33910869      PMCID: PMC8193318          DOI: 10.21873/invivo.12444

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  31 in total

1.  Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer.

Authors:  Hongbing Liu; Ying Wu; Zhaofeng Wang; Yanwen Yao; Fangfang Chen; He Zhang; Yunfen Wang; Yong Song
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

2.  Indications for invasive mediastinal staging for non-small cell lung cancer.

Authors:  Jules Lin; Felix Fernandez
Journal:  J Thorac Cardiovasc Surg       Date:  2018-07-21       Impact factor: 5.209

Review 3.  Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines.

Authors:  Paul De Leyn; Christophe Dooms; Jaroslaw Kuzdzal; Didier Lardinois; Bernward Passlick; Ramon Rami-Porta; Akif Turna; Paul Van Schil; Frederico Venuta; David Waller; Walter Weder; Marcin Zielinski
Journal:  Transl Lung Cancer Res       Date:  2014-08

4.  Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma.

Authors:  Mai Kim; Arifudin Achmad; Tetsuya Higuchi; Yukiko Arisaka; Hideaki Yokoo; Satoshi Yokoo; Yoshito Tsushima
Journal:  J Nucl Med       Date:  2014-12-04       Impact factor: 10.057

5.  The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer.

Authors:  G Kasymjanova; N MacDonald; J S Agulnik; V Cohen; C Pepe; H Kreisman; R Sharma; D Small
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

Review 6.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

7.  Relation between tumor FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following curative resection.

Authors:  Eugene Jeong; Seung Hyup Hyun; Seung Hwan Moon; Young Seok Cho; Byung-Tae Kim; Kyung-Han Lee
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

8.  Retrospective analysis for the false positive diagnosis of PET-CT scan in lung cancer patients.

Authors:  Mingxia Feng; Xuemei Yang; Qiang Ma; Yong He
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.889

9.  PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.

Authors:  Jongmin Lee; Chan Kwon Park; Hyoung-Kyu Yoon; Young Jo Sa; In Sook Woo; Hyo Rim Kim; Sue Youn Kim; Tae-Jung Kim
Journal:  Thorac Cancer       Date:  2018-11-26       Impact factor: 3.500

Review 10.  Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis.

Authors:  A Parsons; A Daley; R Begh; P Aveyard
Journal:  BMJ       Date:  2010-01-21
View more
  1 in total

1.  Comparison of recurrence risk between patients with clinically node-positive and -negative stage I non-small cell lung cancer following surgery: A propensity score matching analysis.

Authors:  Kuo-Yang Huang; Hung-Jen Chen; Ching-Hsiung Lin; Bing-Yen Wang; Ching-Yuan Cheng; Sheng-Hao Lin
Journal:  Thorac Cancer       Date:  2022-05-17       Impact factor: 3.223

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.